Breast Cancer Clinical Trial
Facial Skin Health Tracking Feasibility in Breast Cancer Patients
Summary
This feasibility study will assess if tracking objective and subjective facial skin changes over time is acceptable to pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer. There is no intervention arm and no control group. Skin health will be assessed through the instruments described below, and subjective data will be collected with self-administered questionnaires.
Full Description
There are no studies objectively assessing changes to facial skin health in this population, but tools exist to objectively measure changes thus we have chosen to use those tools to measure skin health. Before embarking on an intervention study showing improvement in skin health and patients' self-image and QOL, we first need to see if 1) it is feasible to measure changes in skin health in this population and 2) if skin health does objectively change over the course of therapy.
Eligibility Criteria
Inclusion Criteria:
Provision to sign and date the consent form
Stated willingness to comply with all study procedures and be available for the duration of the study
Be a pre or perimenopausal woman age 18 or over
Be a patient with a new diagnosis of breast cancer who plans to undergo systemic chemotherapy or endocrine therapy, but who has not yet started treatment
Exclusion Criteria:
Postmenopausal status (one year without a menstrual period)
Pregnant women (pregnancy test not required)
Prior cancer diagnosis of any type other than breast cancer
History of prior treatment with chemotherapy or radiation therapy
Chronic skin disease including scleroderma, discoid lupus, atopic dermatitis, rosacea, eczema, or psoriasis
Use of a retinoid-based prescription facial skin product within the past 11 month
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Aurora Colorado, 80045, United States More Info
Principal Investigator
How clear is this clinincal trial information?